ADIPOQ and Obesity: Circulating serum levels of adiponectin are decreased in patients with obesity, type 2 diabetes, metabolic syndrome, or cardiovascular disease inflammation, and are associated with an increased release of pro-inflammatory cytokines like IL-6 and TNF-α [120].